Home » Newsletters » BioWorld

BioWorld

Jan. 31, 2007

View Archived Issues

Allos Brings In $54M To Fund Pivotal Trials Of PDX, Efaproxyn

Allos Therapeutics Inc. is raising $54 million to fund development of its late-stage cancer compounds. (BioWorld Today) Read More

Amylin, PsychoGenics Focus On CNS Drugs Via New Firm, Psylin

FDA Releases New Drug Safety Strategies To Improve Oversight

Lexicon Trims Staff, Spending To Boost Clinical Ambitions

Ception Closes $63M Series C For Anti-Inflammatory Trials

Other News To Note

Clinic Roundup